Patricio joined AGC Biologics in August 2012 as General Manager and Managing Director of the CMC Biologics A/S based in Copenhagen. He then served as Chief Operating Officer for over two years before the board appointed him to the role of CEO in May of 2019. Patricio has been working in Biologics for the last 20 years. During his career, Patricio has held several key executive positions at MSD AH, Intervet/Schering-Plough, Biogenesis-Bagó and other Biotech companies in Spain, Brazil and Argentina developing, manufacturing and controlling biotechnological products and vaccines for human and animal health. He has acted as change agent in several integration processes and developed strong leadership teams.
Patricio holds a Biochemist degree from University of Buenos Aires and a Master of Business Administration from UCEMA.
Hiroshi joined Asahi Glass Company (AGC) Inc. in 1986 and has been engaged in a variety of assignments during his more than 30 years with the company - including, purchasing, sales of architectural glass and corporate planning. During the period of 1996 to 2000, he also worked in sales operations in Florida, California and Tennessee with a focus on special glass products imported from Japan. Hiroshi joined the Life Science Division of the Chemicals Company of AGC, Inc. in 2016 as a leader of Planning & Accounting Management. Hiroshi was appointed CFO of AGC Biologics operations in Bothell, WA in January 2018.
Hiroshi has a Bachelors degree in Law from Tokyo University, Japan.
Mark joined AGC Biologics in February 2018 as Senior Vice President of Integration Management and Business Excellence. Mark has over 25 years of successful experience leading large-scale business integrations and transformations of Fortune 200 client companies both as the COO of several international management consultancies, as well as with his own management and leadership consultancy corporation.
Mark holds an Executive Management Certification from Harvard Business School, a Master of Science in Organizational Development from Chapman University and a Bachelor of Science in Education from Southern Illinois University.
Kasper joined AGC Biologics in 2006 as a Scientist at the Copenhagen facility and has held the positions of Principal Scientist (2007) and Department Manager (2008) within Process Development. Beginning in 2010, Kasper led the Upstream Process Development teams and in 2011, he led process characterization and validation activities. In 2013, Kasper was appointed Vice President of Process Development and from 2014 – 2017, he served as Vice President of Manufacturing. Mr. Møller then served as General Manager and Site Head for the Copenhagen Facility from 2017 – 2019, before being appointed to the role of CTO in June of 2019. Prior to CMC Biologics, he spent five years as an assistant professor and faculty member at the Technical University of Denmark, conducting research and teaching within fermentation technology and metabolic engineering studies.
Kasper has a Ph.D. in Biochemical Engineering from the Technical University of Denmark.
Ikuo has served as Executive Technical Advisor for AGC Biologics since April 2017. Joining Asahi Glass Co. (AGC) in 1986 as a Chemical Process Engineer in the Chemical Divisional R&D Center, Ikuo has over 30 years of experience in development of Fluorine containing polymer products. During the period of 2005 through 2009, he also worked as a corporate investor in Silicon Valley, CA, where he sought business opportunities for AGC.
Ikuo earned a Masters degree in Chemistry from Yamaguchi University JP and has held the Professional Engineer in Chemistry of Japan as a National Qualification since 2014.
SoYoung joined AGC Biologics in 2015 as Vice President of Legal Affairs. She brings more than 20 years of experience as a corporate attorney and business executive with responsibility for all legal matters, including complex product licensing, research and development, commercial disputes/litigation management, board governance, corporate compliance, HR/Employment, general corporate and transactional matters. Ms. Kwon has served as primary counsel to the board and all board committees and has partnered with management and business leaders to achieve business initiatives.
SoYoung holds a Juris Doctorate from Willamette University College of Law and a Masters of Law in Asian and Comparative Law from the University of Washington School of Law
Daisy joined AGC Biologics in April 2017 as the Global Vice President of Human Resources. She brings over 18 years of professional Human Resources and Operations Management experience from various industries including Financial Services, High Tech and Power Generation, working with organizations ranging in size from start-ups to the global Fortune 100 including serving as the Head of HR for the Tax Credit Group of Marcus and Millichap (TCG) for 4 years and the Head of HR for Idea Entity for more than two years. She joined AGC Biologics (previously CMC Biologics) in April 2017 as the Global Vice President of Human Resources.
Daisy earned a Diplome d’Etudes Collegiales from Marianopolis College (CEGEP) in Montreal, Quebec, a Bachelor of Commerce from McGill University (Major in Human Resource Management and a minor in Entrepreneurship), Montreal Quebec and an Master of Business Administration from Azusa Pacific University, a private Christian university in Southern CA.
Paul joined AGC Biologics in 2015 as Vice President for the Quality Department. He brings more than 25 years of experience in development of protein and small molecule products. Prior to AGC Biologics, he held positions of increasing responsibility at Amgen and Eli Lilly in operations, quality and analytical development.
Paul has a Ph.D. in Chemistry from Texas A&M University and a Bachelor of Science in Applied Chemistry from Harvey Mudd College.
Chris joined AGC Biologics in 2019 as General Manager and Site Head of the Seattle facility. He brings more than 25 years of experience in the development and manufacturing of protein and small molecule products. Mr. Holt worked previously for Lonza, DSM/Patheon and GlaxoSmithKline in the US and Europe in engineering and manufacturing roles of increasing leadership responsibility.
Chris holds a Bachelor of Science in Chemistry from the University of Nottingham and a Masters in Energy Engineering (Mechanical Services) from South Bank University in London.
Dieter Kramer — General Manager and Site Head, Heidelberg Facility
Dieter joined AGC Biologics in July 2018 as the Managing Director of our facility in Heidelberg, Germany. Bringing more than 20 years of combined technical and leadership experience to the organization, prior to joining AGC Biologics, Dieter worked in a similar role at Corden Biochem GmbH, a full service Contract Manufacturing Organization (CMO) also in the biotechnology space. He served from 2011 to 2016 as Managing Director of Sandoz Industrial Products GmbH, an API manufacturing site of the Novartis generic division in Frankfurt am Main, Germany with large-scale fermentation and downstream capabilities. Before this assignment, Dieter held various positions in R&D, manufacturing, project management and general management in the Sandoz/Novartis network in Austria and Germany.
Dieter attended Management Center Innsbruck in Innsbruck, Austria and earned a Master of Business Administration in General Management. He pursued his Masters degree in Technical Chemistry and Biotechnology at the Technical University of Graz in Graz, Austria and completed his education with Höhere Technische Bundeslehranstalt for Chemical Engineering in Wels, Austria.
Naofumi Kagami — General Manager and Site Head, Chiba Facility
Naofumi joined AGC Biologics in 2019 as General Manager and Site Head of the Chiba facility. He brings 25 years of industry experience to his role. He worked previously for Roche Diagnostics, Lonza and Sartorius Stedim in Japan in R&D, marketing and sales roles of increasing leadership responsibility for the life sciences and bio-manufacturing markets.
Naofumi earned a Bachelor of Science degree in Biochemistry and Biophysics from the University of Tokyo and continued on at the institution to complete his Master of Science.
Jeffrey D. Mowery — General Manager and Site Head, Copenhagen Facility
Jeffrey joined AGC Biologics in 2019 as General Manager and Site Head of the Copenhagen facility. He brings 20 years of industry experience in small molecule, biologic and cell/gene therapy production environments. His experience includes working for companies that include Juno Therapeutics, Lonza and Genentech.
Jeffrey earned a Bachelor of Science in Project Management from George Fox University in Newberg, Oregon. He earned his Master of Business Administration at Marylhurst University in Portland, Oregon.